These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9743557)

  • 1. T cell recognition of flanking residues of murine invariant chain-derived CLIP peptide bound to MHC class II.
    Naujokas MF; Southwood S; Mathies SJ; Appella E; Sette A; Miller J
    Cell Immunol; 1998 Aug; 188(1):49-54. PubMed ID: 9743557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner.
    Gautam AM; Yang M; Milburn PJ; Baker R; Bhatnagar A; McCluskey J; Boston T
    J Immunol; 1997 Sep; 159(6):2782-8. PubMed ID: 9300699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
    Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
    J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
    Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
    J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex-specific monoclonal antibody.
    Eastman S; Deftos M; DeRoos PC; Hsu DH; Teyton L; Braunstein NS; Hackett CJ; Rudensky A
    Eur J Immunol; 1996 Feb; 26(2):385-93. PubMed ID: 8617308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
    Thayer WP; Ignatowicz L; Weber DA; Jensen PE
    J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC.
    Liang MN; Lee C; Xia Y; McConnell HM
    Biochemistry; 1996 Nov; 35(47):14734-42. PubMed ID: 8942634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unexpected T-cell diversity in syngeneic graft-versus-host disease revealed by interaction with peptide-loaded soluble MHC class II molecules.
    Hess AD; Thoburn CJ; Chen W; Bright AE
    Transplantation; 2003 Apr; 75(8):1361-7. PubMed ID: 12717231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
    Stumptner P; Benaroch P
    EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permissive recognition of a mycobacterial T-cell epitope: localization of overlapping epitope core sequences recognized in association with multiple major histocompatibility complex class II I-A molecules.
    Harris DP; Vordermeier HM; Arya A; Moreno C; Ivanyi J
    Immunology; 1995 Apr; 84(4):555-61. PubMed ID: 7790029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLIP-region mediated interaction of Invariant chain with MHC class I molecules.
    Powis SJ
    FEBS Lett; 2006 May; 580(13):3112-6. PubMed ID: 16678175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
    Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
    J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural analysis of the interaction of apamin with Ia and its recognition by Ad- or Ab-restricted mouse T cells.
    Regnier-Vigouroux A; Ceard B; Van Rietschoten J; Granier C; Pierres M
    J Immunol; 1989 Nov; 143(10):3167-74. PubMed ID: 2478620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study.
    Yaneva R; Springer S; Zacharias M
    Biopolymers; 2009 Jan; 91(1):14-27. PubMed ID: 18767126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen.
    Hess AD; Thoburn C; Chen W; Miura Y; Van der Wall E
    Clin Immunol; 2001 Oct; 101(1):67-76. PubMed ID: 11580228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional divergence of antigen-specific T-lymphocyte responses in syngeneic graft-versus-host disease.
    Thoburn CJ; Miura Y; Bright EC; Hess AD
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):591-603. PubMed ID: 15319771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformation of MHC class II I-A(g7) is sensitive to the P9 anchor amino acid in bound peptide.
    Gardiner A; Richards KA; Sant AJ; Arneson LS
    Int Immunol; 2007 Sep; 19(9):1103-13. PubMed ID: 17855434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes.
    Bischof F; Wienhold W; Wirblich C; Malcherek G; Zevering O; Kruisbeek AM; Melms A
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12168-73. PubMed ID: 11593032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.